Abstract:Multiple myeloma (MM) is the second most common hematological malignancy of plasma cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the accumulation of malignant plasma cells. The pathogenesis of MM involves the interaction between MM cells and the bone marrow microenvironment through soluble cytokines and cell adhesion molecules, which activate various signaling pathways such as PI3K/AKT/mTOR, RAS/MAPK, JAK/STAT, Wnt/β-catenin, and NF-κB pathways. Aberrant activation of these pathways contributes to the proliferation, survival, migration, and drug resistance of myeloma cells, making them attractive targets for therapeutic intervention. Currently, approved drugs targeting these signaling pathways in MM are limited, with many inhibitors and inducers still in preclinical or clinical research stages. Therapeutic options for MM include non-targeted drugs like alkylating agents, corticosteroids, immunomodulatory drugs, proteasome inhibitors, and histone deacetylase inhibitors. Additionally, targeted drugs such as monoclonal antibodies, chimeric antigen receptor T cells, bispecific T-cell engagers, and bispecific antibodies are being used in MM treatment. Despite significant advancements in MM treatment, the disease remains incurable, emphasizing the need for the development of novel or combined targeted therapies based on emerging theoretical knowledge, technologies, and platforms. In this review, we highlight the key role of signaling pathways in the malignant progression and treatment of MM, exploring advances in targeted therapy and potential treatments to offer further insights for improving MM management and outcomes.

Therapeutic targets in myeloma bone disease

Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies

Myeloma and Bone Disease

Multiple Myeloma and Bone: The Fatal Interaction

Multiple myeloma in the marrow: pathogenesis and treatments

Emerging treatment approaches for myeloma-related bone disease

Myeloma bone and extra-medullary disease: Role of PET/CT and other whole-body imaging techniques

Advances in the pathogenesis of multiple myeloma bone disease

Multiple myeloma, immunotherapy and minimal residual disease

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

Treatment strategies for bone disease

Pathogenesis of bone disease in multiple myeloma: from bench to bedside

Metastatic bone disease: Pathogenesis and therapeutic options

The Proteasome and Myeloma-Associated Bone Disease

Molecular Basis and Potential Molecular Mechanisms of Action in Natural Products as Therapeutic Agents Towards Multiple Myeloma

Myeloma bone disease: Progress in pathogenesis.

Current Novel Targeted Therapeutic Strategies in Multiple Myeloma

Multiple myeloma: signaling pathways and targeted therapy

Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management

[Research Advances on Treatment of Multiple Myeloma Bone Disease--Review].

Multiple Myeloma Therapy: Emerging Trends and Challenges